News

Cancer Research Journal

Dr. Shweta Joshi's group shows a FDA-approved Syk inhibitor (Fostamatinib) can reprogram macrophages, enhance the anti-tumor immune response, and improve the efficacy of Gemcitabine in pancreatic cancer. https://twitter.com/ucsdhealthsci/status/1680986021142630401?s=56&t=Ua4uYIfzI0IPWbaXNqzhpQ 

Curebound Discovery Grant

Joshi lab received a competitive Discovery grant award from Cure bound. This funding will allow us to develop novel therapeutic approaches to improve immunotherapy efficacy in high-risk neuroblastoma. https://lnkd.in/gd26RQ_y .

Postdoc Positions Available: 

Currently seeking highly motivated and dedicated postdoctoral fellows with experience in immunology, oncology, cell biology, and molecular biology. Please send your updated resume and three references to Shweta Joshi, shjoshi@ucsd.edu.

July 2021

Joshi lab received a five-year $ 2.0M R01 grant from NIH.

August 2020

Dr. Joshi’s Lab got funds from “Padres Pedal the Cause” to develop novel immunotherapies for neuroblastoma.